Laboratory Improvement Amendments-certified commercial laboratory for NCF2, CYBA, and NCF1 and was negative. Of note, the commercial NCF1 screen examined mutations only in exon 2, which harbors the 2GT deletion that causes most reported cases of NCF1-related chronic granulomatous disease. 4 WGS revealed a homozygous 579G>A substitution causing a premature stop codon (Trp193X) in NCF1 that had previously been reported as causal for chronic granulomatous disease. 5 Patient 3 was a boy who developed Pneumocystis jiroveci pneumonia during the first year of life. There was no family history of primary immunodeficiency. Immune evaluation demonstrated absent serum IgG and IgA. He had normal numbers of B, T, and natural killer (NK) cells by flow cytometry and had normal T-cell proliferative responses to mitogens and antigens. However, the patient lacked any detectable expression of CD40 ligand (CD154) on T cells after stimulation with ionomycin and phorbol myristate acetate, consistent with a diagnosis of X-linked hyper-IgM syndrome. CD40 ligand gene sequencing was performed at a Clinical Laboratory Improvement Amendmentscertified laboratory and no mutations were found, somewhat conflicting with the CD40L expression results. WGS revealed a novel G>T nucleotide substitution in the CD40 ligand gene on the X-chromosome, resulting in a premature stop codon at . Nonsense mutations in neighboring codons (G227X and Q232X) have been previously reported as causes of X-linked hyper-IgM syndrome. 6, 7 Based on the mutation's absence in control subjects and in Exome Variant Server (EVS; National Heart, Lung, and Blood Institute GO Exome Sequencing Project, Seattle, Wash; http://evs.gs.washington. edu/EVS/), its predicted functional consequence, and the described disease-causing mutations in neighboring codons, this mutation was judged the likely cause of this patient's immune defect.
Patient 4 was a girl who presented in infancy with a history of failure to thrive and recurrent infections. Flow cytometry showed that she had no T or B cells, but had an elevated percentage of NK cells. T-cell proliferation studies showed no responses to mitogens. A diagnosis of severe combined immunodeficiency (SCID) was made. RAG1 and RAG2 genes were sequenced, and no mutations were identified. WGS revealed a homozygous 82-kb deletion spanning exons 1 to 4 in DCLRE1C (see Fig E1, A, in this article's Online Repository at www.jacionline.org).
Patient 5 was a girl who presented in infancy with failure to thrive and recurrent infections. Immune studies showed absent T cells and B cells and no T-cell proliferative responses to mitogens. All her lymphocytes were NK cells. These findings led to a diagnosis of SCID. Gene sequencing was performed at a Clinical Laboratory Improvement Amendments-certified commercial laboratory for RAG1, RAG2, and DCLRE1C, which are known to be associated with NK-phenotype SCID, 8, 9 and the results were negative. WGS revealed a novel heterozygous single nucleotide variant observed at an essential splice site in DCLRE1C. This splice site mutation (c.36212T>A) is absent in controls and in EVS, and is predicted to destroy the canonical splice donor site in intron 5. A splice site variant at the neighboring nucleotide position (c.36211G>T) is associated with SCID. 9 Further investigation revealed an 82-kb deletion involving exons 1 to 4 in DCLRE1C (see Fig E1, B) . The combined presence of this partial deletion and the c.36212T>A (IVS512T>A) splice site mutation is the likely cause of SCID in this patient.
Patient 6 was a girl whose brother had combined immunodeficiency with a predominance of NK cells. She was investigated immunologically at an early age and had normal T-lymphocyte proliferative responses to mitogens, antigens, and allogeneic cells. She did well clinically until around age 7 years, when she became profoundly lymphopenic and developed very low T-cell function. WGS showed a homozygous essential splice site mutation (c.10911 G>T) (IVS111 G>T) in DCLRE1C that was absent in controls. This single nucleotide variant is extremely rare (minor allele frequency 5 0.00023 in EVS). This splice site mutation is predicted to destroy the canonical splice donor site in intron 1. However, given the rarity of this variant and the lack of consanguinity in the family, homozygosity was considered unlikely. Deletion screening showed that the patient also had the same 82-kb hemizygous deletion involving exons 1 to 4 of DCLRE1C observed in patient 5 (see Fig E1, C) , which had resulted in miscalling of the single nucleotide variant as homozygous.
The difference in disease severity between patients 5 and 6 is interesting because both patients are compound heterozygotes for similar deletion but have different essential splice site mutations. Patient 5 had no T-cell function, while patient 6 had normal T-cell function until around age 7 years. To explain the difference in phenotypic severity, we constructed minigenes for each of the 2 newly identified DCLRE1C variants (IVS111 G>T and IVS512 T>A) (see Fig E2 in this article's Online Repository at www. jacionline.org). A decrease in the wild type DCLRE1C (WT-DCLRE1C) isoform was observed in the IVS111 G>T variant construct (Fig 1, A) . Follow-up quantitative RT-PCR of the wild-type and mutant minigene transcript revealed that the variant produced only 16% of the wild-type transcript (Fig 1,  B) . The IVS512 T>A variant construct resulted in a novel isoform in which exon 5 was skipped (Fig 1, C and D) . Both novel isoforms are predicted to result in abnormal gene and/or protein expression and/or function. We examined the mRNA and protein expression of the full-length WT-DCLRE1C cDNA and the IVS512 T>A isoform, in which exon 5 is skipped, using FLAG-tagged constructs (Fig 2, A) . Although both isoforms showed similar expression at the mRNA level, only the wild-type isoform showed a detectable level of protein (Fig 2,  B and C) .
Hence, the IVS111 G>T variant found in patient 6 produced some of the canonical wild-type isoform, suggesting that this mutation decreases the splicing efficiency. The IVS512 T>A variant from patient 5 did not produce any wild-type isoform, but did produce another isoform. This result is consistent with a model in which patient 6 produced enough wild-type Artemis protein to delay the onset of the patient's combined immunodeficiency, resulting in a less severe phenotype.
The use of next-generation sequencing is accepted for investigating undiagnosed genetic conditions. Here, we show the value of WGS in patients with primary immunodeficiency without identified causal mutations. Primary immunodeficiency diseases (PIDs) are highly heterogeneous conditions that would benefit from the application of next-generation sequencing (NGS) in clinical testing. In most cases, PIDs are monogenic and follow simple Mendelian inheritance. However, disease penetrance and expression variability as well as interactions between genetic and environmental factors can contribute to the wide range of phenotypic diversity observed across PIDs. E1 More than 220 PIDs have been described in the scientific literature to date, and new PIDs continue to be reported. E2,E3 Previous attempts to identify the causal mutations underlying PIDs primarily entailed positional cloning or candidate gene sequencing based on known signaling pathways and phenotypic similarity of disease in patients and available murine models. Investigators have also used genome-wide association approaches, which led to the discovery of multiple novel common variable immunodeficiency susceptibility loci. E4 The use of highthroughput NGS technology has helped explain novel causes of some PIDs. Over the last few years, a number of publications have reported newer molecular defects in PID by NGS technology. Recent examples include the use of whole-exome sequencing (WES) in identifying mutations in IKBKB as a cause of combined immunodeficiency (CID), CSF3R as a cause of congenital neutropenia, and CTPS1 associated with defective lymphocyte proliferation and severe EBV infection. E5-E7 With the continued discovery of newer molecular defects in PID, keeping up with the growing literature on inherited mutations in PID can be tedious and time consuming. However, several useful online databases are available to researchers. The Human Gene Mutation Database (http://www.hgmd.org) is a comprehensive collection of mutations in nuclear genes that underlie or are associated with human inherited disease. A valuable database for PID is the Resource of Asian Primary Immunodeficiency Disease (http://web16.kazusa.or.jp/rapid/). This is a freely accessible database that contains information on sequence variation, as well as expression at the mRNA and protein levels, in genes reported from patients with PID.
SCID is a fatal PID syndrome characterized by profound deficiencies of T-and B-cell function. It is known to be caused by mutations in at least 13 different genes, E8,E9 but there are patients with SCID whose mutations remain unknown. Less-severe CID is characterized by impaired but not absent T-and B-cell function. Although some patients with CID have hypomorphic mutations in known SCID-associated genes, the causal mutations for many patients with CID remain elusive. Similarly, although causative mutations for hyper-IgM syndrome have been found in 5 genes, E10,E11 many patients still lack identification of the causal gene mutation. Chronic granulomatous disease (CGD) is caused by mutations in 5 nicotinamide adenine dinucleotide phosphate oxidase structural genes (CYBB, CYBA, NCF1, NCF2, and NCF4).
E12 Mutations in CYBB (gp91phox) cause X-linked CGD and account for nearly two thirds of the cases. All other described CGD cases have an autosomal-recessive pattern of inheritance.
METHODS
All patients were followed at the Immune Deficiency Foundation's Duke University Primary Immunodeficiency Center of Excellence. All studies were performed with the approval of the Duke University Medical Center's Institutional Review Board and with the written informed consent of the patients or their parents.
WGS
WGS was accomplished using paired-end sequencing on the Illumina HiSeq2000 with average coverage of 39. 5 6 5.8 (range, 33.6-50.0) . Reads were aligned to the Human Reference Genome (NCBI36) using BWA software. E13 Single nucleotide variants (SNVs) and insertions/deletions (INDELs) were called and genotypes assigned using SAMtools. E14 Control samples (n > 160) were sequenced contemporaneously in the same laboratory, and variants were called and annotated in a manner similar to the patient genomes.
Identification of likely causal variants
The WGS screens were designed to interrogate highly penetrant genotypes that might account for each patient's PID. Patients were screened for putatively functional rare variants that were absent in a cohort of more than 160 unrelated control subjects and were absent or at very low frequencies in the EVS (National Heart, Lung, and Blood Institute GO Exome Sequencing Project; http://evs.gs.washington.edu/ EVS/) public database. High-quality variants were annotated using the Sequence Variant Analyzer (http://www.svaproject.org/). E15 Standard filtering criteria were applied (SNV quality, SNV consensus score, INDEL consensus score of > _20, INDEL quality > _ 50, number of reads supporting SNV or INDEL > _3). Because variants with known or predicted functional consequences are more likely to be causal of such deleterious phenotypes, only functional variants were further considered: missense and nonsense SNVs, stop loss SNVs, frameshift INDELs, and splice site mutations, or structural variants that overlapped genes. Functional variants present in the proband were prioritized as potentially causal as follows: (1) a homozygous (including hemizygous X variants) genotype lacking homozygosity in controls (recessive and X-linked variants) (minor allele frequency < 0.02) and (2) a compound heterozygous (minor allele frequency < 0.03 for each participating variant) genotype that was not observed together in any controls. Known PID genes were included in the initial evaluation of candidate variants lists generated from these tests. Candidate variants were then further prioritized by gene ontology, with higher weight given to variants in genes with a known role in immune function or known expression in relevant cell types. When no interesting genes were identified by these criteria, heterozygous genotypes in patients with very low frequencies in controls (minor allele frequency < 0.02) were also included. This served as an indirect screen for compound heterozygosity that could have been missed on our initial screen, either because of low coverage of 1 of the 2 causal mutations or because 1 of the 2 causal variants was a copy number variant (CNV).
Identification of structural variation
Structural variations (including INDELs, deletions, duplications, and CNVs) were identified using ERDS (Estimation by Read Depth with SNVs, version 1.06; http://www.utahresearch.org/mingfuzhu/erds/) software. E16 ERDS primarily uses a paired Hidden Markov Model to analyze high-coverage WGS data combining read depth, paired-end, polymorphism, and structural variant signature information with GC corrections. CNVs were detected with default ERDS parameters.
E16
DCLRE1C splicing studies Plasmids. Each human DCLRE1C exon, including approximately 300 bp of flanking intronic sequence, was amplified from genomic DNA derived from PBMCs of healthy volunteers using PrimeSTAR GXL DNA Polymerase (Takara, Otsu Shiga, Japan). DCLRE1C exons were subcloned into the pCR-Blunt II-TOPO vector (Life Technologies, Grand Island, NY) and sequenced. Using pCR-Blunt II-Exon1 and pCR-Blunt II-DCLRE1C-Exon5 as templates, the IVS111 G>T and IVS512 T>A mutants (c.10911G>T and c.36212T>A, respectively) were made by PCR-directed mutagenesis using PfuUltra II Fusion HS DNA Polymerase. The products were phosphorylated by T4 polynucleotide kinase (New England Biolabs, Ipswich, Mass), self-ligated using T4 DNA ligase (Promega, Madison, Wis), and sequenced. Genomic DNAs encoding exons 1 to 3 and exons 3 to 6 were subcloned into pcDNA3.1 (1) vector, generating the Minigene-1 and Minigene-5 wild-type (WT) and mutant constructs, respectively.
The 59 and 39 ends of the human DCLRE1C cDNA sequence were amplified with PrimeSTAR GXL DNA Polymerase. These were subcloned into the pCR-Blunt II-TOPO vector and subjected to sequence analysis (pCR-Blunt II-DCLRE1C-A-WT and pCR-Blunt II-DCLRE1C-B-WT). Using pCR-Blunt II-DCLRE1C-A-WT, the Dexon5 isoform of DCLRE1C was made by PCR-directed mutagenesis to remove exon 5 as described above. A FLAG-tag was also added to each isoform by PCR-directed mutagenesis. FLAG-tagged full-length cDNAs encoding DCLRE1C were subcloned into pcDNA3.1(1) vector, creating pcDNA3.1(1)-DCLRE1C-WT-FLAG and pcDNA3.1(1)-DCLRE1C-Dexon5-FLAG constructs.
Minigene assays. Empty pcDNA3.1 (1) vector, Minigene-1WT, Minigene-1mutant, Minigene-5WT, and Minigene-5mutant were transfected into COS-7 using Lipofectamine 2000 according to standard protocol. Total RNA was extracted from transfectants after 24 hours, and first-strand cDNA encoding the human DCLRE1C minigene was synthesized. DCLRE1C minigene transcript expression levels were detected by semi-quantitative RT-PCR and sequenced. The transcripts of Minigene-1WT and Minigene-1mutant were also detected by quantitative RT-PCR using Taqman one-step PCR Master Mix (Life Technologies) (for primer list, see Table E1 ).
Immunoblotting. Empty pcDNA3.1 (1) vector, pcDNA3.1(1)-DCLRE1C-WT-FLAG, or pcDNA3.1(1)-DCLRE1C-Dexon5-FLAG were transfected into COS-7 cells. Cells were lysed with a solution of RIPA Buffer (Sigma-Aldrich, St Louis, Mo), 1 3 0.5 mol/L EDTA, and 13 protease inhibitor (ThermoScientific, Somerset, NJ) 48 hours after transfection. Lysates were subjected to SDS-PAGE gel and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, Mass). The membranes were incubated with anti-FLAG antibody (1:2000; Sigma-Aldrich) or anti-b-actin (1:10,000; Cell Signalling Technology, Danvers, Mass). Proteins were visualized with the ECL Plus Western Blotting Detection System (GE Healthcare, South Plainfield, NJ).
Verification of variants and communication of results to families
All families underwent genetic counseling at our immunology clinic at the time of participation. The identified variants were confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory before communication to the families.
DISCUSSION
To date, we have performed WGS on 12 primary immunodeficiency disease cases. We identified the causal mutation in 6 (discussed here). Hence, we had a success rate of 50% in identifying the disease-causing mutation.
The use of NGS is accepted for investigating undiagnosed genetic conditions. NGS adds considerable value through its ability to both identify novel and rare mutations in known genes and investigate a broader range of genes than by targeted gene testing.
Commercial laboratories are limited by the nature and cost of targeted gene testing, and sometimes only those gene regions that harbor most of the previously identified mutations are screened. For patients 1 and 2, the causal mutation in exon 7 of NCF1 was missed by targeted gene testing because the commercial NCF1 screen examined mutations only in exon 2, which harbors the 2GT deletion that causes most reported cases of NCF1-related CGD. E17 It remains unclear why the nonsense mutation in CD40 ligand gene we identified in patient 3 was missed by the CLIA-certified laboratory. Of note, measurement of CD40L function by assessing the binding of CD40L to the soluble receptor CD40-muIg is available as a clinical test.
Patient 4 was initially screened for mutations only in RAG1 and RAG2, the only known causes of NK-phenotype SCID at the time of her diagnosis. E18 The Artemis encoding DCLRE1C gene was subsequently also found to cause NK-phenotype SCID.
E19
Hypomorphic DCLRE1C mutations have also been reported as a cause of partial T-and B-lymphocyte immunodeficiency.
E20
The DCLRE1C gene is prone to deletions involving 1 or more of its 14 exons.
E21 One study analyzing DCLRE1C mutations in patients with SCID found that 60% of the alleles had a large deletion, mostly involving exons 1 to 3.
E22 Patient 4 in our study was found to be homozygous for the 82-kb deletion involving exons 1 to 4 in DCLRE1C (Fig E1, A) .
The defect in patient 5 was also missed by a CLIA-certified laboratory when she was tested for DCLRE1C mutations because targeted gene testing at that time lacked the ability to identify gross deletions and was able to discern only nondiagnostic heterozygosity. Patient 6 was the only patient initially screened via WGS. It is worth noting that even if patient 6 had undergone full SCID candidate gene testing (at significant expense), the cause may have been missed unless an exon array or a multiplex ligation-dependent probe amplification was performed to determine the copy number of the DCLRE1C gene, as with patient 5.
Defects involving DCLRE1C gross deletions, as we observed in patients 4 to 6, would likely have been missed by targeted gene testing technology, generating ambiguous results because of PCR failure in Sanger sequencing. Even WES may have missed this causal mutation because inferring CNVs is much more challenging and less reliable with exome data.
E23
The cost of clinical genetic testing in these patients is important to address. For patients 1 and 2, the cost for testing NCF1, NCF2, and CYBA at a CLIA-certified commercial laboratory was $3200 per patient.
Of note, the current cost of sequencing in our research laboratory is around $3200 for WGS and $650 for WES. The current standard turnaround time for WES and WGS at the Duke Center for Human Genome Variation (research laboratory) is 49 days. For urgent cases, rapid sequencing can be done at the Duke Center for Human Genome Variation in about 2 weeks. Standard turnaround time will vary by research or clinical laboratory. Interestingly, a group reported a system that permits WGS with bioinformatics analysis of suspected genetic disorders within 50 hours. This time frame is very promising for emergency use when rapid diagnosis is needed in an emergency or critical care setting. E24 NGS panels for a selected group of genes have become commercially available and are proving to be more popular and economical than sequencing individual genes. One recent report suggests that NGS-based evaluation may be used as a first-line genetic test for cases of PID. E25 Furthermore, NGS may be clinically and economically beneficial in patients who remain undiagnosed despite traditional genetic diagnostic evaluations. E26 NGS has been clearly shown to be a successful approach in identifying causes of Mendelian diseases, even when the condition is seen in a single patient. Variations in data generation across platforms and methods of data interpretation can be challenging in this context, particularly when disease-causing variation is very rare and present in only a single family. However, a set of criteria has recently been proposed for deciding whether the clinical and experimental data are sufficient to establish a causal relationship with only 1 affected individual. E27 There are challenges associated with NGS technology, including the complexity of data analysis and the potential for the mapping and variant calling algorithms to miss variants. Reliability of NGS data analysis is highly dependent on the choice of a reliable control cohort of high quality and depth. In addition, this technology requires extensive interplay between geneticists, clinicians, and bioinformaticians and the analysis can be very complex.
It is also likely that a small proportion of the genome will remain refractory to NGS. WES and WGS offer the advantage of interrogating the entire genome, rather than being limited to only likely gene candidates, and WGS may prove to be faster and less expensive than targeted gene approaches in many cases.
Although the patients studied already had a clinical diagnosis, determining the underlying genetic causes of their diseases is important for several reasons. First, it may have an impact on clinical care. For example, patients with Artemis deficiency are at an increased risk for deleterious effects from ionizing radiation. In addition, we have found that patients and families lacking a definitive genetic diagnosis have emotional distress from lack of information regarding genetic counseling and uncertainty regarding potential future impact on subsequent pregnancies.
The choice between performing WGS or WES is not an easy one. WES is less expensive and more readily available, but can miss disease-causing mutations in noncoding regions. Examples include intronic GATA2 mutations in patients with MonoMAC syndrome E28 and a mutation in the 59 untranslated region of IKBKG (nuclear factor-kappaB essential modifier) in X-linked ectodermal dysplasia with immunodeficiency. E29 Identification of large structural variations such as deletions was formerly problematic with WES. However, recent new analytical approaches make it possible to screen for clinically relevant CNVs using existing exome-based CNV detection methods. E30 Yet, WGS is known to provide more accurate inference about structural variation than WES.
In summary, this work suggests that the application of NGS should be strongly considered in all PID cases in whom the initial studies have not determined the molecular etiology of disease. 
